Literature DB >> 27804988

Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.

Gerhardt Attard1, Emmanuel S Antonarakis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27804988     DOI： 10.1038/nrurol.2016.212

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Authors:  Mary Nakazawa; Emmanuel S Antonarakis; Jun Luo
Journal:  Horm Cancer       Date:  2014-07-22       Impact factor: 3.869

2.  Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.

Authors:  Christof Bernemann; Thomas J Schnoeller; Manuel Luedeke; Konrad Steinestel; Martin Boegemann; Andres J Schrader; Julie Steinestel
Journal:  Eur Urol       Date:  2016-07-26       Impact factor: 20.096

3.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

4.  Plasma AR and abiraterone-resistant prostate cancer.

Authors:  Alessandro Romanel; Delila Gasi Tandefelt; Vincenza Conteduca; Anuradha Jayaram; Nicola Casiraghi; Daniel Wetterskog; Samanta Salvi; Dino Amadori; Zafeiris Zafeiriou; Pasquale Rescigno; Diletta Bianchini; Giorgia Gurioli; Valentina Casadio; Suzanne Carreira; Jane Goodall; Anna Wingate; Roberta Ferraldeschi; Nina Tunariu; Penny Flohr; Ugo De Giorgi; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

5.  Tumor clone dynamics in lethal prostate cancer.

Authors:  Suzanne Carreira; Alessandro Romanel; Jane Goodall; Emily Grist; Roberta Ferraldeschi; Susana Miranda; Davide Prandi; David Lorente; Jean-Sebastien Frenel; Carmel Pezaro; Aurelius Omlin; Daniel Nava Rodrigues; Penelope Flohr; Nina Tunariu; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

6.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

7.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Authors:  Alexander W Wyatt; Arun A Azad; Stanislav V Volik; Matti Annala; Kevin Beja; Brian McConeghy; Anne Haegert; Evan W Warner; Fan Mo; Sonal Brahmbhatt; Robert Shukin; Stephane Le Bihan; Martin E Gleave; Matti Nykter; Colin C Collins; Kim N Chi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

8.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

9.  Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Chandtip Chandhasin; Erica Osbourne; Jun Luo; Marianne D Sadar; Frank Perabo
Journal:  Oncologist       Date:  2016-09-14
  9 in total
  18 in total

1.  MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer.

Authors:  Yanjun Xu; Rui Hou; Qijie Lu; Yang Zhang; Lei Chen; Yuanyi Zheng; Bing Hu
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Prostate cancer: AR-Vs not predictive in mCRPC.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2018-02-27       Impact factor: 14.432

3.  Serum and Plasma Copy Number Detection Using Real-time PCR.

Authors:  Samanta Salvi; Vincenza Conteduca; Filippo Martignano; Giorgia Gurioli; Daniele Calistri; Valentina Casadio
Journal:  J Vis Exp       Date:  2017-12-15       Impact factor: 1.355

4.  Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.

Authors:  Tsung-Chieh Shih; Ruiwu Liu; Chun-Te Wu; Xiaocen Li; Wenwu Xiao; Xiaojun Deng; Sophie Kiss; Ting Wang; Xiao-Jia Chen; Randy Carney; Hsing-Jien Kung; Yong Duan; Paramita M Ghosh; Kit S Lam
Journal:  Clin Cancer Res       Date:  2018-04-17       Impact factor: 12.531

5.  Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.

Authors:  Urszula L McClurg; Nay C T H Chit; Mahsa Azizyan; Joanne Edwards; Arash Nabbi; Karl T Riabowol; Sirintra Nakjang; Stuart R McCracken; Craig N Robson
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

6.  Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation.

Authors:  Xuefu Ji; Jiayi Zhang; Yuguo Tang; Wei Xia; Wei Shi; Dong He; Jie Bao; Xuedong Wei; Yuhua Huang; Yangchuan Liu; Jyh-Cheng Chen; Xin Gao
Journal:  Phys Eng Sci Med       Date:  2021-06-01

Review 7.  A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Ramona F Curpan; Yousef M Hawsawi; Ping Fan; V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2017-11-21       Impact factor: 5.678

8.  High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.

Authors:  Hadjer Dellal; Abdelhay Boulahtouf; Elina Alaterre; Alice Cuenant; Marina Grimaldi; William Bourguet; Céline Gongora; Patrick Balaguer; Philippe Pourquier
Journal:  Cells       Date:  2020-06-16       Impact factor: 6.600

9.  The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.

Authors:  Urszula L McClurg; Mahsa Azizyan; Craig N Robson; Daniel T Dransfield; Nivedita Namdev; Nay C T H Chit; Sirintra Nakjang
Journal:  Oncotarget       Date:  2018-05-18

10.  Metabolic characterization and pathway analysis of berberine protects against prostate cancer.

Authors:  Xianna Li; Aihua Zhang; Hui Sun; Zhidong Liu; Tianlei Zhang; Shi Qiu; Liang Liu; Xijun Wang
Journal:  Oncotarget       Date:  2017-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.